With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Next: Access Our ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Respiratory syncytial virus (RSV) is a leading cause ... levels and to elicit a Th1 immune response. Novavax is testing a postfusion F protein vaccine formulated with alum in both older adults ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said it ...

High levels of neutralizing antibodies to RSV F protein have been ... and to elicit a Th1 immune response. Novavax is testing a postfusion F protein vaccine formulated with alum in both older ...

Novavax's Q3 2024 earnings call and 10-Q reveal ... As I write on 01/13/2025 its history of failures to successfully take flu and RSV vaccines over the finish line to FDA approval, deprives ...

A man who took part in a clinical trial for the development of a Covid vaccine has lashed out at the lingering effects.

Other vaccine stocks also fell, with Novavax and BioNTech both ending more ... for Disease Control and Prevention will recommend for RSV revaccination. But Mock noted that the company expects ...

A Brisbane man who took part in the University of Queensland’s aborted Covid vaccine trial is still returning “false positive” HIV tests four years later.